BACKGROUND AND PURPOSE: Although low levels of adiponectin are associated with coronary heart disease and cardiovascular disease risk factors, it is unclear whether adiponectin levels are related to the risk of developing ischemic stroke. METHODS: We examined the relationship between baseline high-molecular-weight (HMW) adiponectin levels and incident ischemic stroke in postmenopausal women using data and specimens from the Hormones and Biomarkers Predicting Stroke Study, a case-control study nested within the Women's Health Initiative Observational Study. Included were 855 incident ischemic stroke cases and 855 control subjects matched for age, race-ethnicity, date of entry into the cohort, and follow-up time. ORs of incident ischemic stroke associated with baseline HMW adiponectin levels were calculated using conditional logistic regression modeling adjusting for body mass index, type 2 diabetes, hypertension, smoking, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, physical activity, C-reactive protein, and aspirin use. RESULTS: Lower levels of HMW adiponectin were significantly associated with type 2 diabetes, hypertension, higher body mass index, waist circumference, glucose, and insulin levels and lower high-density lipoprotein cholesterol levels. The distribution of incident stroke cases by HMW adiponectin quartiles was 49.9%, 50.5%, 50.7%, and 48.9%, respectively (P=0.96). Multivariable-adjusted ORs of stroke associated with the top 3 quartiles of HMW adiponectin versus the first quartile were 0.99 (95% CI, 0.71 to 1.37), 1.37 (0.99 to 1.91), and 1.25 (0.88 to 1.79), respectively (P trend=0.14). CONCLUSIONS: Despite moderate associations between HMW adiponectin and cardiovascular disease risk factors, we found no evidence of an association between HMW adiponectin levels and incident ischemic stroke in these postmenopausal women.
BACKGROUND AND PURPOSE: Although low levels of adiponectin are associated with coronary heart disease and cardiovascular disease risk factors, it is unclear whether adiponectin levels are related to the risk of developing ischemic stroke. METHODS: We examined the relationship between baseline high-molecular-weight (HMW) adiponectin levels and incident ischemic stroke in postmenopausal women using data and specimens from the Hormones and Biomarkers Predicting Stroke Study, a case-control study nested within the Women's Health Initiative Observational Study. Included were 855 incident ischemic stroke cases and 855 control subjects matched for age, race-ethnicity, date of entry into the cohort, and follow-up time. ORs of incident ischemic stroke associated with baseline HMW adiponectin levels were calculated using conditional logistic regression modeling adjusting for body mass index, type 2 diabetes, hypertension, smoking, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, physical activity, C-reactive protein, and aspirin use. RESULTS: Lower levels of HMW adiponectin were significantly associated with type 2 diabetes, hypertension, higher body mass index, waist circumference, glucose, and insulin levels and lower high-density lipoprotein cholesterol levels. The distribution of incident stroke cases by HMW adiponectin quartiles was 49.9%, 50.5%, 50.7%, and 48.9%, respectively (P=0.96). Multivariable-adjusted ORs of stroke associated with the top 3 quartiles of HMW adiponectin versus the first quartile were 0.99 (95% CI, 0.71 to 1.37), 1.37 (0.99 to 1.91), and 1.25 (0.88 to 1.79), respectively (P trend=0.14). CONCLUSIONS: Despite moderate associations between HMW adiponectin and cardiovascular disease risk factors, we found no evidence of an association between HMW adiponectin levels and incident ischemic stroke in these postmenopausal women.
Authors: N Ouchi; S Kihara; Y Arita; K Maeda; H Kuriyama; Y Okamoto; K Hotta; M Nishida; M Takahashi; T Nakamura; S Yamashita; T Funahashi; Y Matsuzawa Journal: Circulation Date: 1999 Dec 21-28 Impact factor: 29.690
Authors: David J Stott; Paul Welsh; Ann Rumley; Michele Robertson; Ian Ford; Naveed Sattar; Rudi G J Westendorp; J Wouter Jukema; Stuart M Cobbe; Gordon D O Lowe Journal: Int J Epidemiol Date: 2008-10-24 Impact factor: 7.196
Authors: Jorge R Kizer; David Benkeser; Alice M Arnold; Luc Djousse; Susan J Zieman; Kenneth J Mukamal; Russell P Tracy; Christos S Mantzoros; David S Siscovick; John S Gottdiener; Joachim H Ix Journal: J Clin Endocrinol Metab Date: 2012-11-16 Impact factor: 5.958
Authors: Swapnil N Rajpathak; Robert C Kaplan; Sylvia Wassertheil-Smoller; Mary Cushman; Thomas E Rohan; Aileen P McGinn; Tao Wang; Howard D Strickler; Philipp E Scherer; Rachel Mackey; David Curb; Gloria Y F Ho Journal: Stroke Date: 2011-05-05 Impact factor: 7.914
Authors: Deborah Y Ho; Nancy R Cook; Kathryn A Britton; Eunjung Kim; Mark A Creager; Paul M Ridker; Aruna D Pradhan Journal: Circulation Date: 2011-10-24 Impact factor: 29.690
Authors: Aurelian Bidulescu; Jiankang Liu; Zhimin Chen; Demarc A Hickson; Solomon K Musani; Tandaw E Samdarshi; Ervin R Fox; Herman A Taylor; Gary H Gibbons Journal: Front Public Health Date: 2013-05-24
Authors: Ema Kantorová; Ľubica Jesenská; Daniel Čierny; Kamil Zeleňák; Štefan Sivák; Matej Stančík; Peter Galajda; Vladimír Nosáľ; Egon Kurča Journal: Int J Endocrinol Date: 2015-12-10 Impact factor: 3.257